Skip to main content
Account

Table 1 Baseline characteristics of non-SLN positive and non-SLN negative patients

From: Prediction of non-sentinel lymph node metastases in T1–2 sentinel lymph node-positive breast cancer patients undergoing mastectomy following neoadjuvant therapy

Variables

Subgroup

No. of patients

Non-SLN negative

Non-SLN positive

P

(n = 34, 47.9%)

(n = 37, 52.1%)

Side

Left

18(52.9%)

20(54.1%)

0.925

Right

16(47.1%)

17(45.9%)

Menopause

No

21(61.8%)

18(48.6%)

0.267

Yes

13(38.2%)

19(51.4%)

Number of positive SLN

1

20(58.8%)

14(37.8%)

0.189

2

9(26.5%)

13(35.1%)

3

5(14.7%)

10(27.0%)

LNR

 

0.41(± 0.21)

0.63(± 0.31)

< 0.001

Tumor location

Upper outer quadrant

23(67.6%)

21(56.8%)

0.421

Upper inner quadrant

3(8.8%)

4(10.8%)

Lower inner quadrant

1(2.9%)

0(0.0%)

Lower outer quadrant

5(14.7%)

5(13.5%)

Central

2(5.9%)

7(18.9%)

Long axis of LN(Mean ± SB, mm)

 

6.6(± 7.6)

12.4(± 8.8)

0.004

Short axis of LN(Mean ± SB, mm)

 

3.4(± 4.2)

6.9(± 4.8)

0.002

Blood flow

No

20(58.8%)

22(59.5%)

0.957

Yes

14(41.2%)

15(40.5%)

Calcification

No

32(94.1%)

33(89.2%)

0.456

Yes

2(5.9%)

4(10.8%)

Cortex

Normal

21(61.8%)

12(32.4%)

0.013

Thickening

13(38.2%)

25(67.6%)

Lymphatic hilum

Normal

22(64.7%)

18(48.6%)

0.173

Disappear

12(35.3%)

19(51.4%)

Histological grade

1

13(38.2%)

6(16.2%)

0.103

2

19(55.9%)

29(78.4%)

3

2(5.9%)

2(5.4%)

ER

<=10%

10(29.4%)

13(35.1%)

0.607

> 10%

24(70.6%)

24(64.9%)

PR

<=20%

21(61.8%)

16(43.2%)

0.119

> 20%

13(38.2%)

21(56.8%)

HER-2

Negative

27(79.4%)

29(78.4%)

0.915

Positive

7(20.6%)

8(21.6%)

KI-67(Mean ± SB)

< 10%

1(2.9%)

3(8.1%)

0.640

10–30%

7(20.6%)

7(18.9%)

> 30%

26(76.5%)

27(73.0%)

cT

1

11(32.4%)

8(21.6%)

0.308

2

23(67.6%)

29(78.4%)

Response

SD + PD

22(64.7%)

24(64.9%)

0.989

CR + PR

12(35.3%)

13(35.1%)

cN

0

10(29.4%)

7(18.9%)

0.301

1

24(70.6%)

30(81.1%)

  1. Baseline characteristics of non-SLN positive and non-SLN negative patients after NAT. LNR: lymph node ratio; ER: estrogen receptor; PR: progesterone receptor; HER-2: human epidermal growth factor receptor 2; cT: clinical T stage; cN: clinical N stage; SD: stable disease; PD: progressive disease; CR: complete response; PR: partial response